Article

Key clinical point: Local ablative treatment (LAT) combined with systemic therapy demonstrated superior survival outcomes compared with systemic therapy alone and was well tolerated in patients with oligometastatic breast cancer (BC).

Major finding: LAT+systemic treatment vs only systemic treatment significantly improved progression-free survival (hazard ratio [HR] 0.35; P  =  .001) and overall survival (HR 0.13; P < .001). LAT was well tolerated, with only one case of grade 3 toxicity being reported.

Study details: Findings are from a retrospective single-center study including 102 patients with oligometastatic BC, of which 62 and 40 patients received systemic treatment and LAT+systemic treatment, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Glemarec G et al. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes. Breast. 2022 (Dec 29). Doi: 10.1016/j.breast.2022.12.035

Key clinical point: Local ablative treatment (LAT) combined with systemic therapy demonstrated superior survival outcomes compared with systemic therapy alone and was well tolerated in patients with oligometastatic breast cancer (BC).

Major finding: LAT+systemic treatment vs only systemic treatment significantly improved progression-free survival (hazard ratio [HR] 0.35; P  =  .001) and overall survival (HR 0.13; P < .001). LAT was well tolerated, with only one case of grade 3 toxicity being reported.

Study details: Findings are from a retrospective single-center study including 102 patients with oligometastatic BC, of which 62 and 40 patients received systemic treatment and LAT+systemic treatment, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Glemarec G et al. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes. Breast. 2022 (Dec 29). Doi: 10.1016/j.breast.2022.12.035

Key clinical point: Local ablative treatment (LAT) combined with systemic therapy demonstrated superior survival outcomes compared with systemic therapy alone and was well tolerated in patients with oligometastatic breast cancer (BC).

Major finding: LAT+systemic treatment vs only systemic treatment significantly improved progression-free survival (hazard ratio [HR] 0.35; P  =  .001) and overall survival (HR 0.13; P < .001). LAT was well tolerated, with only one case of grade 3 toxicity being reported.

Study details: Findings are from a retrospective single-center study including 102 patients with oligometastatic BC, of which 62 and 40 patients received systemic treatment and LAT+systemic treatment, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Glemarec G et al. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes. Breast. 2022 (Dec 29). Doi: 10.1016/j.breast.2022.12.035

Key clinical point: A low expression of human epidermal growth factor receptor 2 (HER2) did not have any impact on survival outcomes in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: Patients with HER2-low and HER2-0 TNBC had similar overall survival rates (hazard ratio 0.95; P  =  .545).

Study details: Findings are from a retrospective, multicenter analysis including 691 patients with metastatic TNBC, of which 221 patients were classified as having HER2-low TNBC.

Disclosures: This study was supported by grants from Daiichi Sankyo, Pfizer, Novartis, AstraZeneca, Eli Lilly, Seagen, Roche,  and from Ministero della Salture d'Italia. Some authors declared serving as speakers or on advisory boards or receiving honoraria, research grants, or travel grants from several sources, including Daiichi Sankyo, Pfizer, Novartis, Astra Zeneca, Eli Lilly, Seagen, Roche, and others.

Source: Gampenrieder SP et al. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group. ESMO Open. 2022;8(1):100747 (Dec 21). Doi: 10.1016/j.esmoop.2022.100747

Key clinical point: A low expression of human epidermal growth factor receptor 2 (HER2) did not have any impact on survival outcomes in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: Patients with HER2-low and HER2-0 TNBC had similar overall survival rates (hazard ratio 0.95; P  =  .545).

Study details: Findings are from a retrospective, multicenter analysis including 691 patients with metastatic TNBC, of which 221 patients were classified as having HER2-low TNBC.

Disclosures: This study was supported by grants from Daiichi Sankyo, Pfizer, Novartis, AstraZeneca, Eli Lilly, Seagen, Roche,  and from Ministero della Salture d'Italia. Some authors declared serving as speakers or on advisory boards or receiving honoraria, research grants, or travel grants from several sources, including Daiichi Sankyo, Pfizer, Novartis, Astra Zeneca, Eli Lilly, Seagen, Roche, and others.

Source: Gampenrieder SP et al. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group. ESMO Open. 2022;8(1):100747 (Dec 21). Doi: 10.1016/j.esmoop.2022.100747

Key clinical point: A low expression of human epidermal growth factor receptor 2 (HER2) did not have any impact on survival outcomes in patients with metastatic triple-negative breast cancer (TNBC).

Major finding: Patients with HER2-low and HER2-0 TNBC had similar overall survival rates (hazard ratio 0.95; P  =  .545).

Study details: Findings are from a retrospective, multicenter analysis including 691 patients with metastatic TNBC, of which 221 patients were classified as having HER2-low TNBC.

Disclosures: This study was supported by grants from Daiichi Sankyo, Pfizer, Novartis, AstraZeneca, Eli Lilly, Seagen, Roche,  and from Ministero della Salture d'Italia. Some authors declared serving as speakers or on advisory boards or receiving honoraria, research grants, or travel grants from several sources, including Daiichi Sankyo, Pfizer, Novartis, Astra Zeneca, Eli Lilly, Seagen, Roche, and others.

Source: Gampenrieder SP et al. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group. ESMO Open. 2022;8(1):100747 (Dec 21). Doi: 10.1016/j.esmoop.2022.100747

Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who received pyrotinib along with trastuzumab+docetaxel in the neoadjuvant setting achieved a significant improvement in the total pathological complete response (tpCR) rate without experiencing any unprecedented adverse events (AE).

Major finding: Rate of tpCR was significantly higher in the pyrotinib vs placebo group (41% vs 22%; 1-sided P < .0001). The most common grade 3 or 4 AE in the pyrotinib and placebo treatment arms were diarrhea (44.4% and 5.1%, respectively), neutropenia (18.5% and 20.3%, respectively), and decreased white blood cell count (16.3% and 13.6%, respectively).

Study details: Findings are from the phase 3 PHEDRA study including 355 patients with early/locally advanced HER+ BC who were randomly assigned to receive trastuzumab+docetaxel with either pyrotinib or placebo.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Four authors declared being former employees of Hengrui. No other conflicts of interest were reported.

Source: Wu J, Jiang Z, Liu Z, Yang B, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): A double-blind, randomized phase 3 trial. BMC Med. 2022;20(1):498 (Dec 27). Doi: 10.1186/s12916-022-02708-3

Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who received pyrotinib along with trastuzumab+docetaxel in the neoadjuvant setting achieved a significant improvement in the total pathological complete response (tpCR) rate without experiencing any unprecedented adverse events (AE).

Major finding: Rate of tpCR was significantly higher in the pyrotinib vs placebo group (41% vs 22%; 1-sided P < .0001). The most common grade 3 or 4 AE in the pyrotinib and placebo treatment arms were diarrhea (44.4% and 5.1%, respectively), neutropenia (18.5% and 20.3%, respectively), and decreased white blood cell count (16.3% and 13.6%, respectively).

Study details: Findings are from the phase 3 PHEDRA study including 355 patients with early/locally advanced HER+ BC who were randomly assigned to receive trastuzumab+docetaxel with either pyrotinib or placebo.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Four authors declared being former employees of Hengrui. No other conflicts of interest were reported.

Source: Wu J, Jiang Z, Liu Z, Yang B, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): A double-blind, randomized phase 3 trial. BMC Med. 2022;20(1):498 (Dec 27). Doi: 10.1186/s12916-022-02708-3

Key clinical point: Patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who received pyrotinib along with trastuzumab+docetaxel in the neoadjuvant setting achieved a significant improvement in the total pathological complete response (tpCR) rate without experiencing any unprecedented adverse events (AE).

Major finding: Rate of tpCR was significantly higher in the pyrotinib vs placebo group (41% vs 22%; 1-sided P < .0001). The most common grade 3 or 4 AE in the pyrotinib and placebo treatment arms were diarrhea (44.4% and 5.1%, respectively), neutropenia (18.5% and 20.3%, respectively), and decreased white blood cell count (16.3% and 13.6%, respectively).

Study details: Findings are from the phase 3 PHEDRA study including 355 patients with early/locally advanced HER+ BC who were randomly assigned to receive trastuzumab+docetaxel with either pyrotinib or placebo.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Four authors declared being former employees of Hengrui. No other conflicts of interest were reported.

Source: Wu J, Jiang Z, Liu Z, Yang B, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): A double-blind, randomized phase 3 trial. BMC Med. 2022;20(1):498 (Dec 27). Doi: 10.1186/s12916-022-02708-3

Key clinical point: A de-escalated zoledronate schedule (≤6 infusions) did not affect breast cancer (BC)-specific survival outcomes in patients with hormone receptor-positive early BC.

Major finding: After a median follow-up of 96 months, the rates of disease-free survival were similar between patients who received ≤6 and ≥7 infusions (stratified hazard ratio 0.88; log-rank P = .64); however, there was an increase in adverse events, particularly arthralgia (P = .012) and nausea (P = .017), among patients who received ≥7 vs ≤6 infusions.

Study details: Findings are a substudy of the ABCSG-12 trial including 725 premenopausal women with early BC who were randomly assigned to receive hormone therapy (tamoxifen or anastrozole with goserelin) with or without zoledronic acid.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Beltran-Bless AA et al. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Eur J Cancer. 2022;180:108-116 (Dec 31). Doi: 10.1016/j.ejca.2022.12.003

Key clinical point: A de-escalated zoledronate schedule (≤6 infusions) did not affect breast cancer (BC)-specific survival outcomes in patients with hormone receptor-positive early BC.

Major finding: After a median follow-up of 96 months, the rates of disease-free survival were similar between patients who received ≤6 and ≥7 infusions (stratified hazard ratio 0.88; log-rank P = .64); however, there was an increase in adverse events, particularly arthralgia (P = .012) and nausea (P = .017), among patients who received ≥7 vs ≤6 infusions.

Study details: Findings are a substudy of the ABCSG-12 trial including 725 premenopausal women with early BC who were randomly assigned to receive hormone therapy (tamoxifen or anastrozole with goserelin) with or without zoledronic acid.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Beltran-Bless AA et al. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Eur J Cancer. 2022;180:108-116 (Dec 31). Doi: 10.1016/j.ejca.2022.12.003

Key clinical point: A de-escalated zoledronate schedule (≤6 infusions) did not affect breast cancer (BC)-specific survival outcomes in patients with hormone receptor-positive early BC.

Major finding: After a median follow-up of 96 months, the rates of disease-free survival were similar between patients who received ≤6 and ≥7 infusions (stratified hazard ratio 0.88; log-rank P = .64); however, there was an increase in adverse events, particularly arthralgia (P = .012) and nausea (P = .017), among patients who received ≥7 vs ≤6 infusions.

Study details: Findings are a substudy of the ABCSG-12 trial including 725 premenopausal women with early BC who were randomly assigned to receive hormone therapy (tamoxifen or anastrozole with goserelin) with or without zoledronic acid.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Beltran-Bless AA et al. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Eur J Cancer. 2022;180:108-116 (Dec 31). Doi: 10.1016/j.ejca.2022.12.003

Key clinical point: Adding ovarian function suppression (OFS) to adjuvant tamoxifen reduced the risk for recurrence in premenopausal patients with hormone receptor-positive (HR+) breast cancer (BC).

Major finding: Compared with tamoxifen alone, tamoxifen+OFS significantly improved the 12-year disease-free survival (hazard ratio [HR] 0.82; P  =  .03), with the improvement being greater with exemestane+OFS (HR 0.69; 95% CI 0.57-0.83).

Study details: Findings are from the SOFT trial including 3047 premenopausal women with HR+ BC who were randomly assigned to receive 5 years of adjuvant tamoxifen, tamoxifen+OFS, or exemestane+OFS.

Disclosures: This study was supported by Breast Cancer Trials Australia and New Zealand and other sources. The authors declared serving as consultants, advisors, or on speaker’s bureaus or receiving honoraria, research funding, or travel and accommodation expenses from several sources.

Source: Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2022 (Dec 9). Doi: 10.1200/JCO.22.01065

Key clinical point: Adding ovarian function suppression (OFS) to adjuvant tamoxifen reduced the risk for recurrence in premenopausal patients with hormone receptor-positive (HR+) breast cancer (BC).

Major finding: Compared with tamoxifen alone, tamoxifen+OFS significantly improved the 12-year disease-free survival (hazard ratio [HR] 0.82; P  =  .03), with the improvement being greater with exemestane+OFS (HR 0.69; 95% CI 0.57-0.83).

Study details: Findings are from the SOFT trial including 3047 premenopausal women with HR+ BC who were randomly assigned to receive 5 years of adjuvant tamoxifen, tamoxifen+OFS, or exemestane+OFS.

Disclosures: This study was supported by Breast Cancer Trials Australia and New Zealand and other sources. The authors declared serving as consultants, advisors, or on speaker’s bureaus or receiving honoraria, research funding, or travel and accommodation expenses from several sources.

Source: Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2022 (Dec 9). Doi: 10.1200/JCO.22.01065

Key clinical point: Adding ovarian function suppression (OFS) to adjuvant tamoxifen reduced the risk for recurrence in premenopausal patients with hormone receptor-positive (HR+) breast cancer (BC).

Major finding: Compared with tamoxifen alone, tamoxifen+OFS significantly improved the 12-year disease-free survival (hazard ratio [HR] 0.82; P  =  .03), with the improvement being greater with exemestane+OFS (HR 0.69; 95% CI 0.57-0.83).

Study details: Findings are from the SOFT trial including 3047 premenopausal women with HR+ BC who were randomly assigned to receive 5 years of adjuvant tamoxifen, tamoxifen+OFS, or exemestane+OFS.

Disclosures: This study was supported by Breast Cancer Trials Australia and New Zealand and other sources. The authors declared serving as consultants, advisors, or on speaker’s bureaus or receiving honoraria, research funding, or travel and accommodation expenses from several sources.

Source: Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2022 (Dec 9). Doi: 10.1200/JCO.22.01065

Key clinical point: A first-line chemotherapy-free treatment regimen containing endocrine therapy (ET) and human epidermal growth factor receptor 2 (ERBB2)-targeted therapy led to excellent survival outcomes in patients with hormone receptor-positive (HR+) and ERBB2-positive (ERBB2+) metastatic breast cancer (BC).

Major finding: No significant difference was observed in overall survival (hazard ratio [HR] 1.03; P = .80) or progression-free survival (HR 1.00; P > .99) between patients receiving ERBB2-targeted therapy and chemotherapy with or without ET and patients receiving ERBB2-targeted therapy with ET only, regardless of the type of ERBB2-targeted therapy.

Study details: Findings are from a cohort study including 1723 patients with HR+/ERBB2+ metastatic BC who received ERBB2-targeted therapy and chemotherapy with or without ET (n = 1520) or ERBB2-targeted therapy with ET only (n = 203).

Disclosures: This study was supported by Unicancer. The authors declared receiving personal fees, research funding, grants, or travel expenses from several pharmaceutical companies.

Source: Carausu M et al. Association of endocrine therapy for HR+/ERBB2+ metastatic breast cancer with survival outcomes. JAMA Netw Open. 2022;5(12):e2247154 (Dec 15). Doi: 10.1001/jamanetworkopen.2022.47154

Key clinical point: A first-line chemotherapy-free treatment regimen containing endocrine therapy (ET) and human epidermal growth factor receptor 2 (ERBB2)-targeted therapy led to excellent survival outcomes in patients with hormone receptor-positive (HR+) and ERBB2-positive (ERBB2+) metastatic breast cancer (BC).

Major finding: No significant difference was observed in overall survival (hazard ratio [HR] 1.03; P = .80) or progression-free survival (HR 1.00; P > .99) between patients receiving ERBB2-targeted therapy and chemotherapy with or without ET and patients receiving ERBB2-targeted therapy with ET only, regardless of the type of ERBB2-targeted therapy.

Study details: Findings are from a cohort study including 1723 patients with HR+/ERBB2+ metastatic BC who received ERBB2-targeted therapy and chemotherapy with or without ET (n = 1520) or ERBB2-targeted therapy with ET only (n = 203).

Disclosures: This study was supported by Unicancer. The authors declared receiving personal fees, research funding, grants, or travel expenses from several pharmaceutical companies.

Source: Carausu M et al. Association of endocrine therapy for HR+/ERBB2+ metastatic breast cancer with survival outcomes. JAMA Netw Open. 2022;5(12):e2247154 (Dec 15). Doi: 10.1001/jamanetworkopen.2022.47154

Key clinical point: A first-line chemotherapy-free treatment regimen containing endocrine therapy (ET) and human epidermal growth factor receptor 2 (ERBB2)-targeted therapy led to excellent survival outcomes in patients with hormone receptor-positive (HR+) and ERBB2-positive (ERBB2+) metastatic breast cancer (BC).

Major finding: No significant difference was observed in overall survival (hazard ratio [HR] 1.03; P = .80) or progression-free survival (HR 1.00; P > .99) between patients receiving ERBB2-targeted therapy and chemotherapy with or without ET and patients receiving ERBB2-targeted therapy with ET only, regardless of the type of ERBB2-targeted therapy.

Study details: Findings are from a cohort study including 1723 patients with HR+/ERBB2+ metastatic BC who received ERBB2-targeted therapy and chemotherapy with or without ET (n = 1520) or ERBB2-targeted therapy with ET only (n = 203).

Disclosures: This study was supported by Unicancer. The authors declared receiving personal fees, research funding, grants, or travel expenses from several pharmaceutical companies.

Source: Carausu M et al. Association of endocrine therapy for HR+/ERBB2+ metastatic breast cancer with survival outcomes. JAMA Netw Open. 2022;5(12):e2247154 (Dec 15). Doi: 10.1001/jamanetworkopen.2022.47154

Key clinical point: The majority of topical and systemic therapies for atopic dermatitis (AD) effectively reduced pruritus, the most common patient-reported symptom.

Major finding: Topical and systemic treatments led to a mean reduction of 3.32 (99% CI 2.32-4.33) and 3.07 (99% CI 2.58-3.56) points in pruritus score, respectively. Wet-wrap therapy using halometasone (−4.75 points) was the most effective topical treatment, and 30 mg upadacitinib (−4.90 points) was the most effective systemic treatment.

Study details: This study analyzed 22 studies that included patients aged ≥ 10 years with AD who received topical or systemic treatments.

Disclosures: No information on the source of funding was provided. Two authors reported ties with various organizations.

Source: Rodriguez-Le Roy Y et al. Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis. Front Med (Lausanne). 2022;9:1079323 (Dec 22). Doi: 10.3389/fmed.2022.1079323

Key clinical point: The majority of topical and systemic therapies for atopic dermatitis (AD) effectively reduced pruritus, the most common patient-reported symptom.

Major finding: Topical and systemic treatments led to a mean reduction of 3.32 (99% CI 2.32-4.33) and 3.07 (99% CI 2.58-3.56) points in pruritus score, respectively. Wet-wrap therapy using halometasone (−4.75 points) was the most effective topical treatment, and 30 mg upadacitinib (−4.90 points) was the most effective systemic treatment.

Study details: This study analyzed 22 studies that included patients aged ≥ 10 years with AD who received topical or systemic treatments.

Disclosures: No information on the source of funding was provided. Two authors reported ties with various organizations.

Source: Rodriguez-Le Roy Y et al. Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis. Front Med (Lausanne). 2022;9:1079323 (Dec 22). Doi: 10.3389/fmed.2022.1079323

Key clinical point: The majority of topical and systemic therapies for atopic dermatitis (AD) effectively reduced pruritus, the most common patient-reported symptom.

Major finding: Topical and systemic treatments led to a mean reduction of 3.32 (99% CI 2.32-4.33) and 3.07 (99% CI 2.58-3.56) points in pruritus score, respectively. Wet-wrap therapy using halometasone (−4.75 points) was the most effective topical treatment, and 30 mg upadacitinib (−4.90 points) was the most effective systemic treatment.

Study details: This study analyzed 22 studies that included patients aged ≥ 10 years with AD who received topical or systemic treatments.

Disclosures: No information on the source of funding was provided. Two authors reported ties with various organizations.

Source: Rodriguez-Le Roy Y et al. Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis. Front Med (Lausanne). 2022;9:1079323 (Dec 22). Doi: 10.3389/fmed.2022.1079323

Key clinical point: Children and adolescents with atopic dermatitis (AD) are at an increased risk of developing juvenile idiopathic arthritis (JIA).

Major finding: Patients with AD vs control individuals had an increased risk for JIA (adjusted odds ratio [aOR] 1.58; 95% CI 1.41-1.77), especially for psoriatic JIA (aOR 2.75; 95% CI 1.64-4.60).

Study details: This population-based register study included 70,584 patients with AD aged <18 years at the time of the first AD diagnosis and 270,783 age- and sex-matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators for or receiving educational grants, speaker honoraria, or consultation honoraria from various organizations.

Source: Keskitalo PL et al. Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: A Finnish nationwide registry study. J Am Acad Dermatol. 2023 (Jan 3). Doi: 10.1016/j.jaad.2022.12.025

Key clinical point: Children and adolescents with atopic dermatitis (AD) are at an increased risk of developing juvenile idiopathic arthritis (JIA).

Major finding: Patients with AD vs control individuals had an increased risk for JIA (adjusted odds ratio [aOR] 1.58; 95% CI 1.41-1.77), especially for psoriatic JIA (aOR 2.75; 95% CI 1.64-4.60).

Study details: This population-based register study included 70,584 patients with AD aged <18 years at the time of the first AD diagnosis and 270,783 age- and sex-matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators for or receiving educational grants, speaker honoraria, or consultation honoraria from various organizations.

Source: Keskitalo PL et al. Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: A Finnish nationwide registry study. J Am Acad Dermatol. 2023 (Jan 3). Doi: 10.1016/j.jaad.2022.12.025

Key clinical point: Children and adolescents with atopic dermatitis (AD) are at an increased risk of developing juvenile idiopathic arthritis (JIA).

Major finding: Patients with AD vs control individuals had an increased risk for JIA (adjusted odds ratio [aOR] 1.58; 95% CI 1.41-1.77), especially for psoriatic JIA (aOR 2.75; 95% CI 1.64-4.60).

Study details: This population-based register study included 70,584 patients with AD aged <18 years at the time of the first AD diagnosis and 270,783 age- and sex-matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators for or receiving educational grants, speaker honoraria, or consultation honoraria from various organizations.

Source: Keskitalo PL et al. Juvenile idiopathic arthritis in children and adolescents with atopic dermatitis: A Finnish nationwide registry study. J Am Acad Dermatol. 2023 (Jan 3). Doi: 10.1016/j.jaad.2022.12.025

Key clinical point: Treatment of patients with atopic dermatitis (AD) with dupilumab is not associated with the development of primary or recurrent malignancy.

Major finding: Dupilumab-exposed and unexposed patients had comparable incidence rates of primary malignancies (adjusted hazard ratio [aHR], 1.010; P  =  .946), keratinocyte cancers (aHR, 0.994; P  =  .973), and recurrent cancers (aHR, 0.828; P  =  .758) per 1,000 person-years.

Study details: This single-center 5-year retrospective study included 9,707 patients with AD, of which 1,627 patients received dupilumab treatment.

Disclosures: This study did not receive any funding. Some authors declared serving as consultants for and/or receiving research funds from various organizations.

Source: Owji S et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2022 (Dec 26). Doi: 10.1016/j.jaip.2022.12.018.

Key clinical point: Treatment of patients with atopic dermatitis (AD) with dupilumab is not associated with the development of primary or recurrent malignancy.

Major finding: Dupilumab-exposed and unexposed patients had comparable incidence rates of primary malignancies (adjusted hazard ratio [aHR], 1.010; P  =  .946), keratinocyte cancers (aHR, 0.994; P  =  .973), and recurrent cancers (aHR, 0.828; P  =  .758) per 1,000 person-years.

Study details: This single-center 5-year retrospective study included 9,707 patients with AD, of which 1,627 patients received dupilumab treatment.

Disclosures: This study did not receive any funding. Some authors declared serving as consultants for and/or receiving research funds from various organizations.

Source: Owji S et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2022 (Dec 26). Doi: 10.1016/j.jaip.2022.12.018.

Key clinical point: Treatment of patients with atopic dermatitis (AD) with dupilumab is not associated with the development of primary or recurrent malignancy.

Major finding: Dupilumab-exposed and unexposed patients had comparable incidence rates of primary malignancies (adjusted hazard ratio [aHR], 1.010; P  =  .946), keratinocyte cancers (aHR, 0.994; P  =  .973), and recurrent cancers (aHR, 0.828; P  =  .758) per 1,000 person-years.

Study details: This single-center 5-year retrospective study included 9,707 patients with AD, of which 1,627 patients received dupilumab treatment.

Disclosures: This study did not receive any funding. Some authors declared serving as consultants for and/or receiving research funds from various organizations.

Source: Owji S et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. J Allergy Clin Immunol Pract. 2022 (Dec 26). Doi: 10.1016/j.jaip.2022.12.018.

Key clinical point: Fatigue is a common symptom in children with atopic dermatitis (AD), particularly those with moderate-to-severe AD, and thus should be considered in clinical practice and trials.

Major finding: Most children had no (38.6%) or mild (32.1%) parent-proxy fatigue, but 27.2% had moderate fatigue and 2.0% had severe fatigue. Higher proportions of children with moderate-to-severe parent-proxy Patient-Reported Outcome Measurement Information System Pediatric fatigue scores were those with moderate (25.7%/1.4%) and severe (39.3%/5.4%) AD vs mild AD (18.0%/0.0%), as determined by Investigator’s Global Assessment, especially those with 5-6 (44.4%/0.0%) or 7 (44.2%/5.2%) nights of sleep disturbance from eczema.

Study details: This cross-sectional observational study included 248 children aged 0-17 years with AD.

Disclosures: This study was funded by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors declared no conflicts of interest.

Source: Rangel SM et al. Prevalence and associations of fatigue in childhood atopic dermatitis: A cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Dec 21). Doi: 10.1111/jdv.18819

Key clinical point: Fatigue is a common symptom in children with atopic dermatitis (AD), particularly those with moderate-to-severe AD, and thus should be considered in clinical practice and trials.

Major finding: Most children had no (38.6%) or mild (32.1%) parent-proxy fatigue, but 27.2% had moderate fatigue and 2.0% had severe fatigue. Higher proportions of children with moderate-to-severe parent-proxy Patient-Reported Outcome Measurement Information System Pediatric fatigue scores were those with moderate (25.7%/1.4%) and severe (39.3%/5.4%) AD vs mild AD (18.0%/0.0%), as determined by Investigator’s Global Assessment, especially those with 5-6 (44.4%/0.0%) or 7 (44.2%/5.2%) nights of sleep disturbance from eczema.

Study details: This cross-sectional observational study included 248 children aged 0-17 years with AD.

Disclosures: This study was funded by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors declared no conflicts of interest.

Source: Rangel SM et al. Prevalence and associations of fatigue in childhood atopic dermatitis: A cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Dec 21). Doi: 10.1111/jdv.18819

Key clinical point: Fatigue is a common symptom in children with atopic dermatitis (AD), particularly those with moderate-to-severe AD, and thus should be considered in clinical practice and trials.

Major finding: Most children had no (38.6%) or mild (32.1%) parent-proxy fatigue, but 27.2% had moderate fatigue and 2.0% had severe fatigue. Higher proportions of children with moderate-to-severe parent-proxy Patient-Reported Outcome Measurement Information System Pediatric fatigue scores were those with moderate (25.7%/1.4%) and severe (39.3%/5.4%) AD vs mild AD (18.0%/0.0%), as determined by Investigator’s Global Assessment, especially those with 5-6 (44.4%/0.0%) or 7 (44.2%/5.2%) nights of sleep disturbance from eczema.

Study details: This cross-sectional observational study included 248 children aged 0-17 years with AD.

Disclosures: This study was funded by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors declared no conflicts of interest.

Source: Rangel SM et al. Prevalence and associations of fatigue in childhood atopic dermatitis: A cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Dec 21). Doi: 10.1111/jdv.18819